According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that:
- PGN-EDO51 was less effective and safe than defendants had led investors to believe;
- the CONNECT2 study was dangerous or otherwise deficient for purposes of U.S. Food and Drug Administration (“FDA”) approval;
- as a result of all the foregoing, PepGen was likely to halt the CONNECT2 study, and PGN-ED051’s clinical, regulatory, and commercial prospects were overstated; and
- as a result, defendants’ public statements were materially false and misleading at all relevant times.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Attorney Advertising. Prior results do not guarantee a similar outcome.
